Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.41 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | F10 | P00742 | 1/20 | 0.41 |
| ▸ | PLG | P00747 | 1/20 | 0.41 |
| ▸ | F12 | P00748 | 1/20 | 0.41 |
| ▸ | PLAU | P00749 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6138542 | 0.93 | CYP4Z1 (0.41) | SMN1; SMN2L3MBTL1EPHX2KMT2ALMNA | |
| SCHEMBL2294774 | 0.83 | CYP4Z1 (0.39) | CYP3A4TSHRCYP4Z1MAPTTDP1 | |
| SCHEMBL3600555 | 0.83 | SMN1; SMN2 (0.39) | SMN1; SMN2L3MBTL1CA12CA1CA2 | |
| SCHEMBL3594770 | 0.82 | CYP4A11 (0.43) | SMN1; SMN2CA12CA1CA2CA7 | |
| SCHEMBL27623425 | 0.82 | SMN1; SMN2 (0.52) | SMN1; SMN2L3MBTL1CA12CA1CA2 | |
| SCHEMBL9442220 | 0.81 | FOLH1 (0.48) | SMN1; SMN2L3MBTL1CA12CA1CA2 | |
| SCHEMBL9442258 | 0.81 | L3MBTL1 (0.44) | SMN1; SMN2L3MBTL1CA12CA1CA2 | |
| SCHEMBL9658901 | 0.81 | ALDH1A1 (0.47) | CYP3A4TSHRHPGDMAPTTDP1 | |
| SCHEMBL3593772 | 0.81 | L3MBTL1 (0.43) | SMN1; SMN2L3MBTL1CA12CA1CA2 | |
| SCHEMBL4547658 | 0.79 | CYP1A2 (0.39) | SMN1; SMN2CYP1A2KMT2ALMNACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7674825-B2 | Dicarboxylic acid derivatives with pharmaceutical properties | BAYER AKTIENGESELLSCHAFT (DE) | 2010-03-09 | — | — | US | disclosed |
| US-20080058314-A1 | Novel dicarboxylic acid derivatives with pharmaceutical properties | BAYER AKTIENGESELLSCHAFT | 2008-03-06 | — | — | US | disclosed |
| EP-1655280-A1 | Dicarboxylic acid derivates with pharmaceutical properties | Bayer HealthCare AG (DE) | 2006-05-10 | — | — | EP | disclosed |
| EP-1216223-B1 | NOVEL DICARBOXYLIC ACID DERIVATIVES WITH PHARMACEUTICAL PROPERTIES | BAYER HEALTHCARE AG (DE) | 2005-11-09 | — | — | EP | disclosed |
| US-6864287-B1 | Derivatives of dicarboxylic acid having pharmaceutical properties | BAYER AKTIENGESELLSCHAFT (DE) | 2005-03-08 | — | — | US | disclosed |
| EP-1216222-A2 | NOVEL DERIVATIVES OF DICARBOXYLIC ACID HAVING PHARMACEUTICAL PROPERTIES | Bayer Aktiengesellschaft (DE) | 2002-06-26 | — | — | EP | disclosed |
| EP-1216223-A1 | NOVEL DICARBOXYLIC ACID DERIVATIVES WITH PHARMACEUTICAL PROPERTIES | Bayer Aktiengesellschaft (DE) | 2002-06-26 | — | — | EP | disclosed |
| WO-2001019778-A1 | NOVEL DICARBOXYLIC ACID DERIVATIVES WITH PHARMACEUTICAL PROPERTIES | BAYER AKTIENGESELLSCHAFT (DE) | 2001-03-22 | — | — | WO | disclosed |
| WO-2001019776-A2 | NOVEL DERIVATIVES OF DICARBOXYLIC ACID HAVING PHARMACEUTICAL PROPERTIES | BAYER AKTIENGESELLSCHAFT (DE) | 2001-03-22 | — | — | WO | disclosed |
| US-5221760-A | Intermediates, leukotriene antagonists | BAYER AKTIENGESELLSCHAFT (DE) | 1993-06-22 | — | — | US | disclosed |
| US-5159097-A | An arylphosphorous compound as chemical intermediate | BAYER AKTIENGESELLSCHAFT (DE) | 1992-10-27 | — | — | US | disclosed |
| EP-0341551-B1 | ALKENOIC ACID DERIVATIVES | BAYER AG (DE) | 1992-04-01 | — | — | EP | disclosed |
| US-5041638-A | Leucotriene antagonist; treatment of respiratory system disorders, cardiovascular disorders | BAYER AKTIENGESELLSCHAFT (DE) | 1991-08-20 | — | — | US | disclosed |
| EP-0341551-A1 | Alkenoic acid derivatives | BAYER AG (DE) | 1989-11-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058314-A1 | Novel dicarboxylic acid derivatives with pharmaceutical properties | PC, GOT2, SDHA | SMN1; SMN2 3741/4885L3MBTL1 4835/4885CA12 980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.